NEUROIMMUNE PATHOGENETIC RELATIONSHIP BETWEEN THE SYMPATHOADRENAL SYSTEM AND INFLAMMATORY MEDIATORS IN ISCHEMIC HEART DISEASE

Authors

  • Kholmirzayeva M.B Namangan State University Faculty of Medicine Teacher of the Department of Therapy Impulse Medical Institute Author
  • Kholmirzayev S.A Teacher of the Department of Pathology and Microbiology Author

Keywords:

ischemic heart disease, sympathoadrenal system, catecholamines, IL-6, TNF-α, MCP-1, CRP, inflammation, endothelial dysfunction, oxidative stress.

Abstract

 This article analyzes the pathogenetic relationship between sympathoadrenal system activation and inflammatory mediators in ischemic heart disease. According to modern concepts, ischemic heart disease is not explained only by mechanical narrowing of the coronary arteries, but is considered a complex pathological process involving atherosclerotic plaque, endothelial dysfunction, impaired coronary microcirculation, oxidative stress, autonomic imbalance, and low-grade chronic inflammation. Myocardial ischemia activates the sympathoadrenal system and increases catecholamine secretion. As a result, heart rate, myocardial contractility, arterial blood pressure, and myocardial oxygen demand increase. At the same time, catecholamines may affect immune cells, the endothelium, and platelets, thereby enhancing the activity of inflammatory mediators such as IL-6, TNF-α, MCP-1, and CRP. Conversely, inflammatory mediators may impair autonomic regulation and contribute to prolonged sympathetic hyperactivity. Thus, a “neuroimmune vicious circle” is formed: ischemia activates the sympathoadrenal system, while sympathetic hyperactivity intensifies inflammation, oxidative stress, and endothelial dysfunction. These mechanisms play an important role in the progression of ischemic heart disease, atherosclerotic plaque instability, microvascular dysfunction, and adverse cardiovascular outcomes.

References

1.Byrne R.A., Rossello X., Coughlan J.J., Barbato E., et al. 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal. 2023;44(38):3720–3826. doi:10.1093/eurheartj/ehad191.

2.Mach F., Koskinas K.C., Roeters van Lennep J.E., et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal. 2025. doi:10.1093/eurheartj/ehaf190.

3.Wang Y., Liu J., Ma A. Sympathetic Nervous System and Atherosclerosis. International Journal of Molecular Sciences. 2023;24(17):13132. doi:10.3390/ijms241713132.

4.Ridker P.M., Everett B.M., Thuren T., MacFadyen J.G., et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine. 2017;377(12):1119–1131. doi:10.1056/NEJMoa1707914.

5.Nidorf S.M., Fiolet A.T.L., Mosterd A., Eikelboom J.W., et al. Colchicine in Patients with Chronic Coronary Disease. New England Journal of Medicine. 2020;383:1838–1847. doi:10.1056/NEJMoa2021372.

6.Tardif J.C., Kouz S., Waters D.D., Bertrand O.F., et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. New England Journal of Medicine. 2019;381:2497–2505. doi:10.1056/NEJMoa1912388.

7.Williams D.P., Koenig J., Carnevali L., Sgoifo A., Jarczok M.N., Sternberg E.M., Thayer J.F. Heart rate variability and inflammation: A meta-analysis of human studies. Brain, Behavior, and Immunity. 2019;80:219–226. doi:10.1016/j.bbi.2019.03.009.

8.Li G., et al. Meta-analysis on inflammation and autonomic nervous system of coronary heart disease combined with depression. BMJ Open. 2024;14. doi:10.1136/bmjopen-2023-079980.

9.Georgakis M.K., de Lemos J.A., Ayers C., et al. Association of Circulating Monocyte Chemoattractant Protein-1 Levels With Cardiovascular Mortality: A Meta-analysis of Population-Based Studies. JAMA Cardiology. 2021;6(5):587–592. doi:10.1001/jamacardio.2020.5392.

Downloads

Published

2026-06-03